A formal feasibility study of sublingual methadone for breakthrough cancer pain
Neil A Hagen1, Dwight E Moulin, Penny Ma Brasher
1Alberta Health Services Cancer Care, Tom Baker Cancer Centre, Calgary, Alberta, Canada. neil.hagen@albertahealthservices.ca
Abstract:
We conducted a feasibility study of sublingual methadone for breakthrough cancer pain, to determine whether a larger, randomized trial was warranted, and to identify a study design that would be likely to succeed. From approximately 1930 patients in the initial pool, nine patients were enrolled. Five patients completed the study, generating data on 83 discrete episodes of breakthrough cancer pain at optimal dose. Mean pain intensity dropped by 1.7 points (on a 10 point numerical scale) within 10 min of sublingual methadone administration, and by 3.2 points after 15 min. No serious or severe toxicity was encountered. Based on the results of this feasibility study, a larger randomized clinical trial of sublingual methadone for breakthrough cancer pain using this trial model would not be successful. Extensive information obtained from small numbers of carefully studied patients provides proof of concept that sublingual methadone is effective, safe, and well tolerated.
Insights
Sublingual methadone effectively reduces breakthrough cancer pain intensity within 15 minutes. While a larger trial using this specific design is not recommended, the study confirms methadone
Area of Science:
- Oncology
- Pharmacology
- Pain Management
Background:
- Breakthrough cancer pain (BTP) poses a significant challenge in palliative care.
- Existing treatments for BTP may have limitations in efficacy or tolerability.
- Sublingual methadone offers a potential alternative for rapid BTP relief.
Purpose of the Study:
- To assess the feasibility of sublingual methadone for breakthrough cancer pain.
- To determine the suitability of a larger, randomized trial design.
- To identify an optimal study design for future research.
Main Methods:
- Feasibility study involving patients with breakthrough cancer pain.
- Administration of sublingual methadone at optimal doses.
- Data collection on pain intensity reduction and toxicity.
Main Results:
- Significant reduction in pain intensity within 10-15 minutes post-administration.
- Mean pain intensity decreased by 1.7 points at 10 minutes and 3.2 points at 15 minutes.
- No serious or severe toxicity was observed.
Conclusions:
- Sublingual methadone demonstrates efficacy and safety for breakthrough cancer pain.
- The current trial model is not suitable for a larger randomized clinical trial.
- Proof of concept established for sublingual methadone's effectiveness and tolerability.
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
01:25Analgesia and Pain Management